At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 90 enrolled
Drug / intervention
mRNA-1325 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region
In Brief
A Phase 1 clinical trial evaluating mRNA-1325 and Placebo for Zika Virus. Completed, enrolled 90 participants across 3 sites.
Detailed Summary
The clinical study will assess the safety, tolerability, and immunogenicity of mRNA-1325 in healthy adult subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsZika Virus
CountriesUnited States
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedJan 2017
Primary CompletionJul 2019
TodayJul 2026
First PostedJan 9, 2017
Enrollment StartDec 21, 2016
Primary CompletionJul 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.5 years ago
Interventions
mRNA-1325biological
Escalating dose levels
Placeboother